Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Biogen Inc. (NASDAQ:BIIB) have earned an average rating of “Moderate Buy” from the thirty-two ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $220.5714.

A number of research firms recently issued reports on BIIB. Oppenheimer lifted their target price on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Jefferies Financial Group restated a “buy” rating on shares of Biogen in a research note on Monday, July 13th. HC Wainwright reaffirmed a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Morgan Stanley decreased their target price on shares of Biogen from $224.00 to $222.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 8th. Finally, Citigroup raised their price target on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st.

Biogen Price Performance

BIIB opened at $202.19 on Monday. Biogen has a 12 month low of $124.56 and a 12 month high of $219.72. The company has a fifty day simple moving average of $199.78 and a 200 day simple moving average of $189.95. The stock has a market cap of $29.85 billion, a P/E ratio of 21.69 and a beta of 0.16. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the company earned $3.02 earnings per share. Biogen’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts expect that Biogen will post 11.29 EPS for the current year.

Hedge Funds Weigh In On Biogen

A number of institutional investors have recently added to or reduced their stakes in BIIB. Reflection Asset Management bought a new stake in shares of Biogen during the fourth quarter worth about $25,000. WPG Advisers LLC increased its position in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp bought a new position in shares of Biogen in the 4th quarter worth $30,000. WFA of San Diego LLC bought a new position in shares of Biogen in the second quarter valued at $32,000. Finally, Root Financial Partners LLC boosted its stake in Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.